Cover Image
市場調查報告書

骨質疏鬆症治療藥的全球市場:2015年∼2019年

Global Osteoporosis Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 295852
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
骨質疏鬆症治療藥的全球市場:2015年∼2019年 Global Osteoporosis Drugs Market 2015-2019
出版日期: 2015年05月06日 內容資訊: 英文 84 Pages
簡介

全球骨質疏鬆症治療藥市場,預計從2014年到2019年之間,以4.14%的年複合成長率擴大。這個成長的主要原因之一為,全球人口的高齡化發展。

本報告提供全球骨質疏鬆症治療藥市場現狀分析與未來預測、成長要素和課題、主要供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 所謂骨質疏鬆症
  • 流行病學和人口統計
  • 風險因素
  • 症狀
  • 診斷
  • 治療

第7章 骨質疏鬆症的治療主要的發展

第8章 市場形勢

  • 市場概要
    • 市場規模與預測
  • 美國市場
    • 市場規模與預測
  • 歐洲市場
    • 市場規模與預測
  • 波特的五力分析

第9章 骨質疏鬆症治療藥的全球市場:各治療分類

  • 骨質疏鬆症治療藥的全球市場:各治療分類的預測
  • 骨吸收抑制治療
  • 蛋白質融化治療 (合成代謝的治療)

第10章 骨質疏鬆症治療藥的全球市場:各治療線

第11章 開發平台評估

第12章 骨質疏鬆症治療藥的全球市場:各地區

  • 骨質疏鬆症治療藥的全球市場:各地區的預測
  • 南北美洲
    • 市場規模與預測
  • 歐洲、中東、非洲地區
    • 市場規模與預測
  • 亞太地區
    • 市場規模與預測

第13章 購買標準

第14章 市場成長因素

第15章 成長因素與其影響

第16章 市場課題

第17章 成長因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
    • 供應商排行榜
    • 主要治療藥的評估
    • Amgen
    • Eli Lilly
    • Merck
    • Novartis
  • 其他卓越供應商

第21章 主要供應商分析

  • Amgen
  • Eli Lilly
  • Merck & Co. Inc.
  • Novartis AG

第22章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5759

About osteoporosis

Osteoporosis, or porous bone, is a disease characterized by low bone density and structural deterioration of bone tissue, leading to fragile bones. As bones becomes fragile, risk of fracture increases. Osteoporosis primarily affects women, but can also affect men. In women, bone loss occurs rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement is too slow. Risk factors for osteoporosis include gender, age, low body weight, ethnicity, and family history. Some of the risk factors that can be manipulated include sex hormones, medication use, intake of calcium and vitamins, alcohol intake, and smoking.

Technavio's analysts forecast the global osteoporosis drugs market to grow at a CAGR of 4.14 percent over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global osteoporosis drugs market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, clinical stage pipeline molecules developed for the treatment of osteoporosis are discussed.

Technavio's report, Global Osteoporosis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC; it also covers the global osteoporosis drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other prominent vendors

  • Abiogen Pharma
  • Deltanoid Pharmaceuticals
  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • IMMD
  • Ligand Pharmaceuticals
  • NPS Pharma
  • Pantarhei Bioscience
  • Pfizer
  • PhytoHealth
  • Radius Health
  • UPSHER-SMITH LABORATORIES
  • Zosano Pharma

Market driver

  • Increase in aging population
  • For a full, detailed list, view our report

Market challenge

  • Multiple expiries of patents
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness about bone health
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding Osteoporosis
  • 06.2. Epidemiology and Demography
  • 06.3. Risk Factors
  • 06.4. Symptoms
  • 06.5. Diagnosis
  • 06.6. Treatment

07. Key Development in Osteoporosis Therapy

08. Market Landscape

  • 08.1. Market Overview
    • 08.1.1. Market Size and Forecast
  • 08.2. Osteoporosis Drugs Market in US
    • 08.2.1. Market Size and Forecast
  • 08.3. Osteoporosis Drugs Market in Europe
    • 08.3.1. Market Size and Forecast
  • 08.4. Five Forces Analysis

09. Market Segmentation by Therapeutic Class

  • 09.1. Global Osteoporosis Drugs Market by Therapeutic Class 2014-2019
  • 09.2. Antiresorptive Medications
  • 09.3. Anabolic Medications

10. Market Segmentation by Line of Therapy

  • 10.1. Global Osteoporosis Drugs Market by Line of Therapy

11. Pipeline Assessment

  • 11.1. Key Information about Pipeline Candidates

12. Geographical Segmentation

  • 12.1. Global Osteoporosis Drugs Market by Geographical Segmentation 2014-2019
  • 12.2. Osteoporosis Drugs Market in Americas
    • 12.2.1. Market Size and Forecast
  • 12.3. Osteoporosis Drugs Market in EMEA
    • 12.3.1. Market Size and Forecast
  • 12.4. Osteoporosis Drugs Market in APAC
    • 12.4.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
    • 20.1.3. Vendor Ranking 2014
    • 20.1.4. Competitive Assessment of Major Drugs
    • 20.1.5. Amgen
    • 20.1.6. Eli Lilly
    • 20.1.7. Merck
    • 20.1.8. Novartis
  • 20.2. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Amgen
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Product Portfolio by Revenue 2013
    • 21.1.5. Business Segmentation by Revenue 2012 and 2013
    • 21.1.6. Geographical Segmentation by Revenue 2013
    • 21.1.7. Business Strategy
    • 21.1.8. Recent Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Eli Lilly
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation by Revenue
    • 21.2.4. Sales by Geography
    • 21.2.5. Business Strategy
    • 21.2.6. Key Information
    • 21.2.7. SWOT Analysis
  • 21.3. Merck & Co. Inc.
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis
  • 21.4. Novartis AG
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis

22. Other Reports in this Series

List Of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Interpretation of BMD Results
  • Exhibit 3: Global Osteoporosis Drugs Market 2014-2019 ($ billion)
  • Exhibit 4: Osteoporosis Drugs Market in US 2014-2019 ($ billion)
  • Exhibit 5: Osteoporosis Drugs Market in Europe 2014-2019 ($ billion)
  • Exhibit 6: Segmentation of Global Osteoporosis Drugs Market by Geography 2014
  • Exhibit 7: Segmentation of Global Osteoporosis Drugs Market by Geography 2019
  • Exhibit 8: Osteoporosis Drugs Market in Americas 2014-2019 ($ billion)
  • Exhibit 9: Osteoporosis Drugs Market in EMEA 2014-2019 ($ billion)
  • Exhibit 10: Osteoporosis Drugs Market in APAC 2014-2019 ($ billion)
  • Exhibit 11: Segmentation of Global Osteoporosis Drugs Market by Geography 2014-2019
  • Exhibit 12: Revenue Comparison of Top Osteoporosis Drugs for First Three Quarters 2014 ($ million)
  • Exhibit 13: YoY Growth Rate and Global Revenue of Prolia 2010-2013 ($ million)
  • Exhibit 14: Revenue of Prolia by Country/Region 2010-2013 ($ million)
  • Exhibit 15: YoY Growth Rate and Global Revenue of Evista 2010-2013 ($ million)
  • Exhibit 16: Revenue of Evista by Country/Region 2010-2013 ($ million)
  • Exhibit 17: YoY Growth Rate and Global Revenue of Forteo 2010-2013 ($ million)
  • Exhibit 18: Revenue of Forteo by Country/Region 2010-2013 ($ million)
  • Exhibit 19: YoY Growth Rate and Global Revenue of Fosamax 2011-2014 ($ million)
  • Exhibit 20: YoY Growth Rate and Global Revenue of Reclast/Aclasta 2010-2013 ($ million
  • Exhibit 21: Revenue of Reclast/Aclasta by Country/Region 2010-2012 ($ million)
  • Exhibit 22: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 23: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 24: Amgen: Business Segmentation by Revenue 2012 and 2013 ($ billion)
  • Exhibit 25: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 26: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 27: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 28: Eli Lilly: Sales by Geography 2013
  • Exhibit 29: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 30: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 ($ billion)
  • Exhibit 31: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 32: Novartis AG: Business Segmentation
  • Exhibit 33: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 34: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
  • Exhibit 35: Novartis AG: Revenue by Geographical Segmentation 2013
Back to Top